bisoprolol has been researched along with Cardiovascular Diseases in 17 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A comparative study on the efficacy and safety of bisoprolol and sustained release metoprolol succinate in patients with arterial hypertension (AH), cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) was conducted." | 5.19 | [Efficacy and safety of bisoprololal in hypertensive patients with cardiovascular disease and chronic obstructive pulmonary disease]. ( Chernikov, MV; Derevianchenko, MV; Lopushkova, IuE; Statsenko, ME, 2014) |
| "The authors performed a double-blinded, placebo-controlled, multicenter trial to compare the effect of bisoprolol with that of placebo on 1-yr composite outcome including cardiovascular mortality, nonfatal myocardial infarction, unstable angina, congestive heart failure, and cerebrovascular insult." | 5.12 | Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-contro ( Bestmann, L; Blumenthal, S; Boltres, A; Borgeat, A; Furrer, L; Hersberger, M; Hofer, C; Kälin, G; Lucchinetti, E; Müller, A; Schulz, C; Spahn, DR; Wacker, J; Zaugg, M; Zollinger, A, 2007) |
| "We sought to compare the effects of two beta-blockers, metoprolol and bisoprolol, as the most commonly used drugs in cardiology, on glucose and lipid profiles in patients with cardiovascular diseases." | 3.91 | Comparison of the Effects of Metoprolol and Bisoprolol on Lipid and Glucose Profiles in Cardiovascular Patients. ( Aldosary, AH; Almeman, AA; Beshir, YA, 2019) |
| " Careful monitoring is recommended for possible new symptoms, such as emergence/increase of shortness of breath, cough or changes in dosing of other drugs (for example, increased frequency of using short-acting bronchodilators)." | 1.62 | [Possibilities and limitations of the use of beta-blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease]. ( Karoli, NA; Rebrov, AP, 2021) |
| " The aim of the present study was to examine the variability of bioavailability (F) of bisoprolol in routinely treated Japanese patients and intestinal absorption characteristics of the drug." | 1.39 | Variability of bioavailability and intestinal absorption characteristics of bisoprolol. ( Fujii, N; Hashimoto, Y; Horie, A; Inoue, H; Ishida, K; Nishimura, M; Nozawa, T; Taguchi, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Castaño-Amores, C | 1 |
| Díaz-Villamarín, X | 1 |
| Pérez-Gutiérrez, AM | 1 |
| Antúnez-Rodríguez, A | 1 |
| Pozo-Agundo, A | 1 |
| Moreno-Escobar, E | 1 |
| Sánchez-Ramos, JG | 1 |
| Martínez-González, LJ | 1 |
| Dávila-Fajardo, CL | 1 |
| Karoli, NA | 1 |
| Rebrov, AP | 1 |
| Huang, KY | 1 |
| Tseng, PT | 1 |
| Wu, YC | 1 |
| Tu, YK | 1 |
| Stubbs, B | 1 |
| Su, KP | 1 |
| Matsuoka, YJ | 1 |
| Hsu, CW | 1 |
| Lin, CH | 1 |
| Chen, YW | 1 |
| Lin, PY | 1 |
| AlHabeeb, W | 1 |
| Mrabeti, S | 1 |
| Abdelsalam, AAI | 1 |
| Turner, RM | 1 |
| Fontana, V | 1 |
| Bayliss, M | 1 |
| Whalley, S | 1 |
| Santoyo Castelazo, A | 1 |
| Pirmohamed, M | 1 |
| Almeman, AA | 1 |
| Beshir, YA | 1 |
| Aldosary, AH | 1 |
| Ishida, K | 1 |
| Horie, A | 1 |
| Nishimura, M | 1 |
| Taguchi, M | 2 |
| Fujii, N | 1 |
| Nozawa, T | 2 |
| Inoue, H | 2 |
| Hashimoto, Y | 2 |
| Statsenko, ME | 1 |
| Derevianchenko, MV | 1 |
| Chernikov, MV | 1 |
| Lopushkova, IuE | 1 |
| Fi, Z | 1 |
| Szentes, V | 1 |
| Schouten, O | 1 |
| Poldermans, D | 1 |
| Visser, L | 1 |
| Kertai, MD | 1 |
| Klein, J | 1 |
| van Urk, H | 1 |
| Simoons, ML | 1 |
| van de Ven, LL | 1 |
| Vermeulen, M | 1 |
| Bax, JJ | 1 |
| Lameris, TW | 1 |
| Boersma, E | 1 |
| Biondi, B | 1 |
| Palmieri, EA | 1 |
| Klain, M | 1 |
| Schlumberger, M | 1 |
| Filetti, S | 1 |
| Lombardi, G | 1 |
| Tahara, K | 1 |
| Igarashi, N | 1 |
| Nonomura, M | 1 |
| Kato, B | 1 |
| Igawa, A | 1 |
| Pikto-Pietkiewicz, W | 1 |
| Zaugg, M | 1 |
| Bestmann, L | 1 |
| Wacker, J | 1 |
| Lucchinetti, E | 1 |
| Boltres, A | 1 |
| Schulz, C | 1 |
| Hersberger, M | 1 |
| Kälin, G | 1 |
| Furrer, L | 1 |
| Hofer, C | 1 |
| Blumenthal, S | 1 |
| Müller, A | 1 |
| Zollinger, A | 1 |
| Spahn, DR | 1 |
| Borgeat, A | 1 |
| Body, SC | 1 |
| Schwinn, DA | 1 |
| Meyer, C | 1 |
| Bühler, FR | 1 |
| Haeusler, G | 1 |
5 reviews available for bisoprolol and Cardiovascular Diseases
| Article | Year |
|---|---|
Pharmacogenetic polymorphisms affecting bisoprolol response.
Topics: Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Blood Pressure; Cardiovascular Diseases; Humans; | 2021 |
Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Cardiovascular Diseases; Ce | 2021 |
Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Cardiovascular Diseases; Ethanolamines; Heart | 2022 |
[The benefits of carvedilol therapy in the treatment of patients with high cardiovascular risk].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Bisoprolol; Carbazoles; Cardi | 2016 |
Subclinical hyperthyroidism: clinical features and treatment options.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Cardiovascular Diseases; Female; Humans; Hyperthyroid | 2005 |
3 trials available for bisoprolol and Cardiovascular Diseases
9 other studies available for bisoprolol and Cardiovascular Diseases
| Article | Year |
|---|---|
[Possibilities and limitations of the use of beta-blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiovascular Diseases; Heart Failure; Humans; Pulmonary D | 2021 |
Comparison of the Effects of Metoprolol and Bisoprolol on Lipid and Glucose Profiles in Cardiovascular Patients.
Topics: Antihypertensive Agents; Bisoprolol; Cardiovascular Diseases; Cross-Sectional Studies; Electrocardio | 2019 |
Variability of bioavailability and intestinal absorption characteristics of bisoprolol.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Biological Availability; Bisoprolol; Cardiovascular Di | 2013 |
Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study.
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Cardiovascular Diseases; Drug Therapy, Combination; | 2004 |
Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Alleles; Bisoprolol; Blood Pressure; Cardiovascular Diseases; Chr | 2005 |
[Adrenergic beta-Antagonists in prevention of cardiovascular complications in major non-cardiac surgery].
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Cardiovascular Diseases; Clinical Trials as Topic; Di | 2006 |
Limitations of genetic findings that are not in Hardy-Weinberg equilibrium.
Topics: Adrenergic beta-Antagonists; Anesthesia, Spinal; Bisoprolol; Cardiomyopathy, Dilated; Cardiovascular | 2008 |
New drugs in the cardiovascular arena.
Topics: Amlodipine; Bisoprolol; Cardiovascular Agents; Cardiovascular Diseases; Humans; Quinolines; Sotalol; | 1993 |
Optimization of beta-blockers for cardiovascular care.
Topics: Adrenergic beta-Antagonists; Biological Availability; Bisoprolol; Cardiovascular Diseases; Half-Life | 1986 |